
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE has received an optimistic boost in its commercial uptake assumptions for the VLA15 vaccine in Europe, aligning them with expectations in the US, thereby enhancing revenue potential. The strong immune responses reported following a third yearly booster of the VLA15 Lyme vaccine candidate in both adults and children suggest promising efficacy, which may lead to increased demand and sales. Despite a temporary suspension of the Ixchiq vaccine by the FDA, the overall earnings performance met expectations, indicating resilience in the company's financial health amid regulatory challenges.
Bears say
Valneva SE faces significant risks that contribute to a negative outlook, primarily due to potential clinical and regulatory setbacks, as well as commercial risks from competing vaccine products and lower-than-expected sales. Recent safety concerns regarding its chikungunya vaccine, Ixchiq, have raised doubts about its competitiveness against alternatives such as Bavarian Nordic's offering, despite claims of superior long-term protection. The company has also removed all projected U.S. sales for Ixchiq from its financial models and is anticipating limited commercial uptake in Europe, reflecting a cautious approach amid these challenges.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares